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DRP (p < 0.05). All those regulations are dose dependent and
time dependent.
Conclusions: The FM1 induce the TLR7 signal Transduction
passageway and serial reactions in it. One of the Mechanism
of DRP curing the Inﬂuenza Virus FM1 is effecting on NF-úB
through inhibiting MyD88 in order to regulate the target
gene expression downstream in that signal passageway.
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PP-064 Reactivation of herpes viruses in the central
[CNS] and peripheral nervous systems [PNS]:
One hundred years from Ramsay Hunt clinical
description to PCR veriﬁcation
S. Bogger Goren*. Zamenhoff Medical Center, Tel Aviv,
Israel
The clinical spectrum of chronic or recurrent manifestations
of CNS and PNS diseases suspected to be related to the
group of Herpes Viruses has been expanded considerably
during the last hundred years since J. Ramsay Hunt ﬁrst
deﬁned in 1907 a syndrome of Zoster Oticus accompanied
by peripheral facial nerve paralysis which bears his name,
Ramsay Hunt Syndrome [RHS], and suggested its association
with Varicella zoster virus reactivation.
In this paper the long term [up to 30 years] clinical evolution
of severe, incapacitating attacks of a complex of neurologic
symptoms in two adult women will be presented together
with its diagnostic dilemmas.
These patients were seen by various specialists and
were subjected to numerous diagnostic procedures to
investigate and verify various presumptive non infectious
CNS, orthopedic or ENT disorders. Variable therapeutic
approaches have failed to alleviate their symptoms. Invasive
therapeutic procedures offered to the patients were refused
by them.
Based on meticulous clinical history and physical
examination, the possibility of recurrent reactivations
of VZV in these patients was contemplated (bearing in
mind the less frequent presentations of RHS), and the
patients were put on full dose courses of Acyclovir (Zovirax
or Valtrex). A dramatic and almost immediate clinical
subjective relief and obvious disappearance of symptoms
ensued. Maintenance on a daily-based low dose Acyclovir for
the following months prevented any further exacerbations
and the patients regain full activity and quality of life.
The contribution of new virological diagnostic techniques
in general, and PCR, in particular, to the identiﬁcation and
understanding of variable chronic and recurrent CNS and
PNS diseases and disorders in general, and VZV involvement
in particular, is discussed.
PP-065 Survey of the seroprevalence of CMV among
hemodialysis patients in Urmia, Iran
Z. Rostam, Z.R. Khameneh*, N. Sepehrvand, F. Eslamlu.
Urmia University Medical Science, Iran
Background and Aim: Cytomegalovirus (CMV) causes
infection in immunocompromised, transplant recipients
and those who receive blood transfusion frequently. Risk
factors for primary CMV infection are blood transfusion
(including clotting factors, etc), recipients of infected
transplants, hemodialysis and the frequency of dialysis in
a week. This study aimed to determine the prevalence of
cytomegalovirus (CMV) antibodies in end-stage renal disease
(ESRD) patients which undergo hemodialysis.
Material and Methods: This study has a cross-sectional
design, which is executed in 2007 among hemodialysis
patients in Urmia, Iran. Sera of 84 Hemodialysis patients
have been investigated by CMV-speciﬁc immunoglobulin G
(IgG) using a CMV IgG enzyme-labeled antigen test.
Collected data were analyzed by descriptive statistics and
chi-square test via SPSS software ver11.5.
Results: In our study, 84 patients who regularly underwent
hemodialysis were studied. Forty-four patients were male
and 40 female with the range 23 82 years age. In the
time of evaluation, 65 patients (77.4%) were anti-CMV IgG
positive and 6 (7.1%) were anti-CMV IgM positive. There
was no relationship between the antibody titer and dialysis
duration, or frequency of HD in a week.
Conclusion: We recommend that every patient who has
undergone hemodialysis received blood products free of
CMV. Development of a vaccine against cytomegalovirus is
essential and could be very life & cost-saving.
PP-066 Survey of the seroprovalence of HTLV I/II in
hemodialysis patients and blood donors in
Urmia
Z. Rostam, Z.R. Khameneh*, M. Baradaran, N. Sepehrvand.
Urmia University Medical Science, Iran
Introduction: HTLV is a virus from retroviridae family.
It is a cause of Lukemia/Lymphoma disease in adults,
Tropical spastic paralysis, HTLV associated myelopathy,
spastic paraparesis, (HAM/TSP) and some nervous system
disease and etc. It is transmitted by means of blood products
via blood transfusion to recipients.
Material and Methods: This study has a cross-sectional
design, which is executed from April of 2005 until
January of 2006 among healthy blood donors and in 2006
among hemodialysis patients in Urmia, Iran. The serum of
2046 blood donors and 95 Hemodialysis patients has been
investigated by enzyme-linked immunosorbent assay (ELISA)
for anti HTLV-I/II and positive cases has been conﬁrmed by
western blot.
Results: There were 1910 male persons (93.4%) among
2046 donors, and 136 cases (6.6%) were female. Serum
of 1997 cases (97.6%) was negative, and 49 cases (2.6%)
were positive as a result of ELISA tests. Positive cases were
investigated by western blot and 37 cases (75.5%) were
negative, 5 persons (10.2%) were IND and 7 persons (14.3%)
were HTLV positive. Among these seven persons, there are
6 cases (85.6%) with HTLV-I, and only one person (14.3%)
with HTLV-I/II infection. Total serologic prevalence of HTLV
in healthy blood donors is 0.34%.
Conclusion: Observation of such a high serologic prevalence
in the population of blood donors in Urmia city,
suggesting the high probability of transmission through blood
transfusion, and so screening of blood donors for human
T-lymphocyte virus is essential and has suggested.
PP-067 Blood safety and prevalence of transfusion
transmissible viral infections among donors at
the Red Cross Blood Bank in Gondar
E. Diro1 *, S. Alemu1, A.G. Yohannes2. 1Department of
Internal Medicine, Gondar University, 2Department of
HIV/AIDS, Alert Hospital, Ethiopia
Background: Even though millions of lives are saved by
blood transfusion, unsafe transfusion is also putting millions
of people at risk of Transfusion Transmissible Infections
(TTI).
Objective: To measure the magnitude of TTIs and related
risk factors among blood donors.
Setting: Ethiopian Red Cross Blood Bank at the Gondar
University Hospital in Northwest Ethiopia.
Methods: Cross-sectional study among volunteer blood
donors at the Red Cross Blood Bank in Gondar University
Hospital.
Results: Consecutive 600 adult voluntary donors from April
to July 2004 were included. Their mean age was 28± 10.4
years, and 66% were urban dwellers. Donors were farmers
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(30.7%), daily laborers (22.7%) and students (20%). All were
ﬁrst time donors, and 75% of the donations were replace-
ment donations. The prevalence of HIV, Hepatitis B surface
antigen (HBsAg) and Hepatitis C virus (HCV) infections were
4.5% (95CI: 3.0 6.6), 8.2% (95CI: 6.2 10.7) and 5.8% (95CI:
4.2 8.1) respectively. In univariate analysis, HCV and HIV
infections were associated (OR: 5.36, 95CI: 2 14.3).
Conclusion: The prevalence of TTIs among blood donors
is very high and the majorities of blood donors are
replacement or paid donors with one or more of the risk
factors for TTIs implying that blood transfusion is unsafe.
These ﬁndings call for the urgent implementation of the
national strategy of safe blood transfusion in Ethiopia.
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PP-068 Survey of Anti-HBc and Anti-HBs prevalence in
HBsAg-negative blood donors in Tehran
Z. Alizadeh*, Z. Shariﬁ, S. Samiei. Iranian Blood Transfusion
Organization-Research Center, Iran
Background: Current serological screening for blood-borne
hepatitis viruses has reduced the risk of post-transfusion
hepatitis dramatically. Occult hepatitis B virus (HBV)
infection might allow the release of viremic units into the
blood supply network if blood is tested only for hepatitis B
surface antigen (HBsAg). The screening for antibody to HBc
(anti-HBc) has been shown as an alternative test for the
detection of HBV infection.
Objective: The aim of this study was to evaluate HBV
infection markers prevalence in HBsAg-negative blood
donors.
Methods: In this descriptive cross-sectional study (in 2007),
2000HBsAg-negative samples were collected from blood
transfusion centers in Tehran. All HBsAg-negative samples
were tested for anti-HBc using ELISA method. Then all
HBsAg-negative and anti-HBc-positive samples were tested
for anti-HBs by the same method. Data were analyzed
statistically using chi-square test.
Results: 199 out of the 2000 HBsAg-negative blood donors
(9.95%) were anti-HBc-positive. Out of the 199 anti-HBc-
positive samples tested for anti-HBs, 149 were anti-HBs-
positive (75%), and 100 had an antibody titer greater than
100 IU/mL (50.3%).
Conclusion: In our study, the prevalence of anti-HBc
in HBsAg-negative blood donors was high. While anti-
HBc-positive blood may be a potential source of HBV
transmission, routine application of anti-HBc screening is
not feasible in our country, as it would seriously limit the
blood supply. Therefore more sensitive techniques such as
Minipool PCR testing after virus enrichment is essential for
detecting HBVDNA in HBsAg-negative chronic HBV carriers.
PP-069 Development of RFLP-PCR assay to identify
Aspergillus species isolated from clinical and
environmental specimens
K. Diba1 *, H. Mirhendi2, N. Jalalizand3, A. Namaki4.
1Department of Parasitology and Mycology, Faculty of
Medicine, Urmia University/Medical Sciences, Urmia, Iran,
2Department of Parasitology and Mycology, shool of Public
Healths, Tehran University/Medical Sciences, Tehran,
Iran, 3Molecular Biology Center, Esfehan Health Research
Center, Tehran University/Medical Sciences, Esfehan, Iran,
4Harsin Hospital, Kermanshah University/Medical Sciences,
Kermanshah, Iran
Aspergillus species are most abundant and widely
distributed in soil, water, air, seed and food. These species
are associated with allergic bronchopulmonary disease,
mycotic keratitis, otomycosis, nasal sinusitis and invasive
infection.In this study we attempted to set up a PCR-RFLP
for identiﬁcation of the most common Aspergillus species.
Test samples were collected from clinical specimens
including sputum, sinus discharge, bronchoalveolar lavage,
nail scrapped and environmental specimens including
hospital wards and outdoors. PCR products ITS regions
in rDNA gene were digested directly and individually by
the restriction enzyme MwoI by incubation at 37ºC, then
subjected to electrophoresis in a 2% agarose gel and then
were visualized with a UV System Gel Document. Totally
205 Aspergillus isolates of our study included; 153 (75%)
environmental and 52 (25%) clinical isolates. A. ﬂavus
isolated more frequently from environmental samples
112 (55%) followed by A. niger 65 (31.7%), A. fumigatus
18 (8.7%), A. nidulans and A. parasiticus 2 (1%). RFLP
method using restriction enzyme MwoI was successful to
discriminate eight medically important Aspergillus species.
We concluded that our PCR-RFLP method using the
restriction enzyme MwoI is a rapid (during 8 10 hours)
and reliable test for colony identiﬁcation of at least the
most important Aspergillus species.
Table 1: The fragment size of ITS1-ITS2 PCR products after digestion with
the enzyme MwoI for various Aspergillus species
Species cutting size
A. fumigatus 207, 125, 108, 29, 21, 9
A. ﬂavus 325, 98, 65, 40, 20
A. niger 192, 175, 120, 108, 30, 21, 9
A. terreus 220, 109, 106, 96, 29, 9
A. nidulans 162, 135, 104, 31, 29, 9
A. clavatus 210, 125, 106
A. ochraceus 420, 90, 39, 9
A. amstelloidami 286, 106, 100, 29, 9
A. ﬁcheri 200, 140, 120
Table 2. The frequency of Aspergillus species isolated from clinical and
environmental sources
Species No Aspergillus strains identiﬁed by RFLP
Total no. of
specimens
Environmental
specimens
Clinical
specimens
No. % No. % No. %
A. ﬂavus 36 69.2 76 49.7 112 55
A. niger 4 7.6 61 39.8 65 31.7
A. fumigatus 7 13.5 11 7.2 18 8.7
A. nidulans 1 1.9 1 0.6 2 1.0
A. tereus 1 1.9 0 0 1 0.5
A. parasiticus 1 1.9 1 0.6 2 1.0
A. penicilloid 0 0 1 0.6 1 0.1
A. tamarii 0 0 1 0.6 1 0.5
A. ochraceus 1 1.9 0 0 1 0.5
A. sojae 1 1.9 0 0 1 0.5
A. niveus 0 0 1 0.6 1 0.5
Total 52 100 153 100 205 100
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